What about Duvelisib for CLL (chronic lymphocytic leukemia)?
Friends,
This
week in the Beyond the Basics/Treatment section of our website, we’ve posted an
article about another treatment under investigation called IPI-145 or duvelisib,
a PI3 kinase inhibitor. You can read about how it works, the data that has been
released and ongoing clinical trials here. [http://cllsociety.org/2016/05/ipi-145-duvelisib-cll/]
In
other news, the FDA expanded the Imbruvica® (ibrutinib) label to include
overall survival data in previously untreated CLL and added a new indication
for small lymphocytic lymphoma (SLL) patients. Read more about it in our News
section here. [http://cllsociety.org/2016/05/fda-expands-imbruvica-label-include-os-data-plus-new-indication-sll/]
THANK YOU AGAIN TO OUR READER
POLL PARTICIPANTS!
Data analysis is in progress and we are really excited with the preliminary
results. We really appreciate the time you spent to contribute to our research
and look forward to sharing the data in the future.
In the
meantime….
Stay strong.
We are all in this together.
Brian Koffman, MD
Volunteer Medical Director of the CLL Society
Labels: Chronic lymphocytic leukemia, CLL, duvelisib, ibrutinib, IPI-145
posted by Brian Koffman at
9:34 PM
1 Comments:
We're struggling, as a culture, with the consequences of the over- and mis-use of associations from epidemiological data about cancer risks www.cancerhelpline.in
Post a Comment
Subscribe to Post Comments [Atom]
<< Home